Case Studies
Real-world analyses powered by IMX Data's healthcare claims dataset.
Quarterly claims data reveals the explosive growth of GLP-1 drugs — who's prescribing, who's paying, and where the market is heading.
Quarterly claims data reveals the explosive growth of ADC drugs — who's prescribing, who's paying, and where the market is heading.
10 years of claims data tracks SGLT-2i's evolution from diabetes therapy to cardiovascular cornerstone — market share, indications, and access barriers.
8 years of retinal-injection claims track the shift from off-label Avastin and Eylea toward durable next-gen agents — agent mix, real-world dosing intervals, site of care, and payer.
Pharmacy and medical claims linked on the same patient track the IL-23 class from the p40 originator to p19-selective agents and the first oral — benefit mix, real-world dosing intervals, indication mix, prescriber specialty, and post-LOE biosimilar erosion.
Research
In-depth analyses and white papers from the IMX Data research team.
Leveraging Alternative Healthcare
Data Sources for Investment Analysis
Data Sources for Investment Analysis
In a concerning trend, a growing number of older adults find themselves compelled to
make agonizing choices, sacrificing fundamental necessities to cope with the
escalating burden of healthcare costs.
View